Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral vs Parenteral Antibiotic Treatment for Infective Endocarditis
NCT05398679Phase 4Recruiting
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Aug 2022
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cefaclor, ciprofloxacin, clindamycin, dicloxacillin, fusidic acid and 8 more in infective endocarditis (IE) (2 arms), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoints: Number of unplanned hospitalizations at 24 months, Number of all-cause mortality at 24 months and 2 more. Started Aug 2022; status: recruiting.
02
Drugs
cefaclorciprofloxacinclindamycindicloxacillinfusidic acid
03
Conditions
infective endocarditis (IE)
Beyond the preview
Go deeper on NCT05398679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05398679.